165 related articles for article (PubMed ID: 26941446)
1. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.
Harter P; du Bois A; Mahner S; Pfisterer J; Ortmann O; Marth C; Fink D; Hilpert F; Wagner U; Sehouli J
Geburtshilfe Frauenheilkd; 2016 Feb; 76(2):147-149. PubMed ID: 26941446
[TBL] [Abstract][Full Text] [Related]
2. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.
Harter P; Bogner G; Chiva L; Cibula D; Concin N; Fotopoulou C; Gonzalez-Martin A; Guyon F; Heinzelmann-Schwarz V; Kridelka F; Mahner S; Marmé F; Marth C; Morice P; Novák Z; Papadia A; Ray-Coquard I; Redecha M; Redondo A; Schwameis R; Sehouli J; Undurraga M; Van Gorp T; Vergote I
Bull Cancer; 2024 Mar; 111(3):277-284. PubMed ID: 36967330
[TBL] [Abstract][Full Text] [Related]
3. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.
Harter P; Mahner S; Hilpert F; Runnebaum I; Ortmann O; Mustea A; Sehouli J; du Bois A; Wagner U;
Geburtshilfe Frauenheilkd; 2013 Mar; 73(3):221-223. PubMed ID: 24771913
[TBL] [Abstract][Full Text] [Related]
4. Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):847. PubMed ID: 29445924
[TBL] [Abstract][Full Text] [Related]
5. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P; Sehouli J; Reuss A; Hasenburg A; Scambia G; Cibula D; Mahner S; Vergote I; Reinthaller A; Burges A; Hanker L; Pölcher M; Kurzeder C; Canzler U; Petry KU; Obermair A; Petru E; Schmalfeldt B; Lorusso D; du Bois A
Int J Gynecol Cancer; 2011 Feb; 21(2):289-95. PubMed ID: 21270612
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Bakrin N; Classe JM; Pomel C; Gouy S; Chene G; Glehen O
J Visc Surg; 2014 Oct; 151(5):347-53. PubMed ID: 25168575
[TBL] [Abstract][Full Text] [Related]
7. [Ovarian cancer -- can peritoneal therapy be regarded as new standard?].
du Bois A; Schmalfeldt B; Meier W; Sehouli J; Pfisterer J
Zentralbl Gynakol; 2006 Aug; 128(4):202-6. PubMed ID: 16835814
[TBL] [Abstract][Full Text] [Related]
8. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.
de Bree E; Helm CW
Expert Rev Anticancer Ther; 2012 Jul; 12(7):895-911. PubMed ID: 22845405
[TBL] [Abstract][Full Text] [Related]
10. Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.
Bespalov VG; Kireeva GS; Belyaeva OA; Kalinin OE; Senchik KY; Stukov AN; Gafton GI; Guseynov KD; Belyaev AM
J Surg Oncol; 2016 Mar; 113(4):438-42. PubMed ID: 26710749
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study.
Le Brun JF; Campion L; Berton-Rigaud D; Lorimier G; Marchal F; Ferron G; Oger AS; Dravet F; Jaffre I; Classe JM
Ann Surg Oncol; 2014 Oct; 21(11):3621-7. PubMed ID: 24819120
[TBL] [Abstract][Full Text] [Related]
12. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B; du Bois A; Burges A; Emons G; Fink D; Gropp M; Hasenburg A; Jäger W; Kimmig R; Kiechle M; Kommoss F; Kreienberg R; Kuhn W; Lück HJ; Meier W; Münstedt K; Ortmann O; Pfisterer J; Richter B; Runnebaum I; Schröder W; Sehouli J; Tanner B; Wagner U; Weis J
Zentralbl Gynakol; 2006 Feb; 128(1):11-7. PubMed ID: 16450281
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an Asian perspective.
Tan WJ; Wong JF; Chia CS; Tan GH; Soo KC; Teo MC
Ann Surg Oncol; 2013 Dec; 20(13):4219-23. PubMed ID: 24008554
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
16. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
Kim JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Lee KH; Lee SH; Kim SJ
J Surg Oncol; 2010 Feb; 101(2):149-55. PubMed ID: 20035540
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach.
Hayes-Jordan A; Lopez C; Green HL; Xiao LC; Huh W; Herzog CE
Pediatr Surg Int; 2016 Jan; 32(1):71-3. PubMed ID: 26500075
[TBL] [Abstract][Full Text] [Related]
18. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
[TBL] [Abstract][Full Text] [Related]
20. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
